A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Authors:
- Hiroshi FukamachiHFHiroshi Fukamachi
- Seon-Kyu KimSKSeon-Kyu Kim
- Jiwon KohJKJiwon Koh
- Hye Seung LeeHLHye Seung Lee
- Yasushi SasakiYasushi Sasaki
- Kentaro YamashitaKYKentaro Yamashita
- Taketo NishikawajiTNTaketo Nishikawaji
- Shu ShimadaSSShu Shimada
- Yoshimitsu AkiyamaYAYoshimitsu Akiyama
- Sun-Ju ByeonSBSun-Ju Byeon
- Dong-Hyuck BaeDBDong-Hyuck Bae
- Keisuke OkunoKeisuke Okuno
Open Access
- 12 March 2019
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-23
Abstract
Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS). Pathological analysis suggested that some diffuse-type GCs developed from intestinal-type GCs. We established patient-derived xenograft (PDX) lines from diffuse-type GCs, and searched for drugs that suppressed their growth. Diffuse-type GCs were classified into subtypes by their gene expression profiles. mTOR inhibitor temsirolimus strongly suppressed the growth of PDX-derived diffuse-type GC-initiating cells, which was regulated via Wnt-mTOR axis. These cells were microsatellite unstable (MSI) or chromosomally unstable (CIN), inconsistent with TCGA report. Diffuse-type GCs in TCGA cohort could be classified into two clusters, and GS subtype was major in cluster I while CIN and MSI subtypes were predominant in cluster II where PDX-derived diffuse-type GC cells were included. We estimated that about 9 and 55% of the diffuse-type GCs in cluster II were responders to mTOR inhibitors and checkpoint inhibitors, respectively, by identifying PIK3CA mutations and MSI condition in TCGA cohort. These ratios were far greater than those of diffuse-type GCs in cluster I or intestinal-type GCs. Further analysis suggested that diffuse-type GCs in cluster II developed from intestinal-type GCs while those in cluster I from normal gastric epithelial cells. mTOR inhibitors and checkpoint inhibitors might be useful for the treatment of a subset of diffuse-type GCs which may develop from intestinal-type GCs.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP15K06832, JP25253081, JP16H06276, 16K08661, AA005)
- Japan Agency for Medical Research and Development (JP17ck0106017)
- Ministry of Education, Culture, Sports, Science and Technology (221S0001)
- Korea Research Institute of Bioscience and Biotechnology (KRIBB Research Initiative Program)
This publication has 79 references indexed in Scilit:
- CD49fhigh Cells Retain Sphere-Forming and Tumor-Initiating Activities in Human Gastric TumorsPLOS ONE, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse‐type gastric carcinoma‐initiating cells is inhibited by TGF‐βThe Journal of Pathology, 2012
- Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistanceProceedings of the National Academy of Sciences, 2011
- mTOR as a therapeutic target in patients with gastric cancerInternational Journal of Cancer, 2011
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis InhibitorsMolecular Cancer Therapeutics, 2011
- Relation between outcomes and localisation of p-mTOR expression in gastric cancerBritish Journal of Cancer, 2009
- Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomasVirchows Archiv, 2008
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- The prevalence of PIK3CA mutations in gastric and colon cancerEuropean Journal of Cancer, 2005